To evaluate the safety and tolerability of belimumab given for 24 months in patients persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable to aPL [refractory and/or non-criteria manifestations of the antiphospholipid syndrome (APS)].

Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol

Sciascia, Savino
Co-first
;
Radin, Massimo
Co-first
;
Cecchi, Irene;Barinotti, Alice;Rubini, Elena;Rossi, Daniela;Fenoglio, Roberta;Menegatti, Elisa;Roccatello, Dario
Last
2023-01-01

Abstract

To evaluate the safety and tolerability of belimumab given for 24 months in patients persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable to aPL [refractory and/or non-criteria manifestations of the antiphospholipid syndrome (APS)].
2023
41
3
597
604
Sciascia, Savino; Radin, Massimo; Cecchi, Irene; Barinotti, Alice; Rubini, Elena; Rossi, Daniela; Fenoglio, Roberta; Vaccarino, Antonella; Menegatti, Elisa; Roccatello, Dario
File in questo prodotto:
File Dimensione Formato  
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory andor non-criter.pdf

Accesso riservato

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 313.58 kB
Formato Adobe PDF
313.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1880107
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact